Phase 3 Failure Keeps AstraZeneca and Ionis Out of a Growing Heart Disease Market
An RNA therapy from partners Ionis Pharmaceuticals and AstraZeneca failed a pivotal study as a treatment for a…
AstraZeneca and Ionis’ stocks drop significantly on Wainua ATTR-CM trial failure
Both AstraZeneca and Ionis’ stocks took a hit at market open on 9 July after the companies announced…